These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32691164)

  • 1. Functional impairment outcomes in clinical trials of different ADHD medications: post hoc responder analyses and baseline subgroup analyses.
    Coghill DR; Werner-Kiechle T; Farahbakhshian S; Bliss C; Robertson B; Huss M
    Eur Child Adolesc Psychiatry; 2021 May; 30(5):809-821. PubMed ID: 32691164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.
    Stein MA; Sikirica V; Weiss MD; Robertson B; Lyne A; Newcorn JH
    CNS Drugs; 2015 Nov; 29(11):953-62. PubMed ID: 26547425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder.
    Banaschewski T; Johnson M; Lecendreux M; Zuddas A; Adeyi B; Hodgkins P; Squires LA; Coghill DR
    CNS Drugs; 2014 Dec; 28(12):1191-203. PubMed ID: 25139785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder.
    Banaschewski T; Soutullo C; Lecendreux M; Johnson M; Zuddas A; Hodgkins P; Adeyi B; Squires LA; Coghill D
    CNS Drugs; 2013 Oct; 27(10):829-40. PubMed ID: 23893527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
    Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
    Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Wilens TE; Robertson B; Sikirica V; Harper L; Young JL; Bloomfield R; Lyne A; Rynkowski G; Cutler AJ
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Kosheleff AR; Hull JT; Liranso T; Qin P; Busse GD; O'Neal W; Fava M; Faraone SV; Rubin J
    J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):214-226. PubMed ID: 33600233
    [No Abstract]   [Full Text] [Related]  

  • 9. Psychometric validation of the Weiss Functional Impairment Rating Scale-Parent Report Form in children and adolescents with attention-deficit/hyperactivity disorder.
    Gajria K; Kosinski M; Sikirica V; Huss M; Livote E; Reilly K; Dittmann RW; Erder MH
    Health Qual Life Outcomes; 2015 Nov; 13():184. PubMed ID: 26577642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship Between Symptomatic and Functional Improvement and Remission in a Treatment Response to Stimulant Trial.
    Weiss M; Childress A; Mattingly G; Nordbrock E; Kupper RJ; Adjei AL
    J Child Adolesc Psychopharmacol; 2018 Oct; 28(8):521-529. PubMed ID: 30036076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Weiss Functional Impairment Rating Scale-Parent Form for assessing ADHD: evaluating diagnostic accuracy and determining optimal thresholds using ROC analysis.
    Thompson T; Lloyd A; Joseph A; Weiss M
    Qual Life Res; 2017 Jul; 26(7):1879-1885. PubMed ID: 28220338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of peer relations and social activities to treatment with viloxazine extended-release capsules (Qelbree
    Faraone SV; Gomeni R; Hull JT; Busse GD; Lujan B; Rubin J; Nasser A
    Brain Behav; 2023 Apr; 13(4):e2910. PubMed ID: 36847750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychometric properties of a modified version of the Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P) in a clinical sample of children with aggressive behavior.
    Kernder T; Doepfner M; Dose C; Goertz-Dorten A
    Qual Life Res; 2019 Jan; 28(1):241-251. PubMed ID: 30276506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder.
    Faraone SV; Gomeni R; Hull JT; Busse GD; Melyan Z; Rubin J; Nasser A
    Eur Child Adolesc Psychiatry; 2023 Mar; 32(3):491-499. PubMed ID: 34581911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children.
    Nasser A; Liranso T; Adewole T; Fry N; Hull JT; Chowdhry F; Busse GD; Cutler AJ; Jones NJ; Findling RL; Schwabe S
    Clin Ther; 2020 Aug; 42(8):1452-1466. PubMed ID: 32723670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating minimal important differences for several scales assessing function and quality of life in patients with attention-deficit/hyperactivity disorder.
    Hodgkins P; Lloyd A; Erder MH; Setyawan J; Weiss MD; Sasané R; Nafees B
    CNS Spectr; 2017 Feb; 22(1):31-40. PubMed ID: 27535815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychometric properties of the Weiss Functional Impairment Rating Scale parent and self-reports in a Norwegian clinical sample of adolescents treated for ADHD.
    Haugan AJ; Sund AM; Thomsen PH; Lydersen S; Nøvik TS
    Nord J Psychiatry; 2021 Jan; 75(1):63-72. PubMed ID: 32749193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Huss M; McBurnett K; Cutler AJ; Hervás A; Bliss C; Gao J; Dirks B; Newcorn JH
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):432-443. PubMed ID: 30064718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.